Aurinia Pharmaceuticals (AUPH) Financials

$15.19 -0.03 (-0.20%)

Closing price 05/26/2026 04:00 PM Eastern

Extended Trading

$15.25 +0.06 (+0.39%)

As of 05:14 AM Eastern

Annual Income Statements for Aurinia Pharmaceuticals

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-23	-71	-54	-88	-103	-181	-108	-78	5.75	287
Consolidated Net Income / (Loss)	-23	-71	-53	-88	-103	-181	-108	-78	5.75	287
Net Income / (Loss) Continuing Operations	-23	-71	-54	-88	-103	-181	-108	-78	5.75	287
Total Pre-Tax Income	-23	-71	-53	-88	-103	-180	-106	-77	7.45	114
Total Operating Income	-25	-47	-55	-91	-104	-181	-111	-92	-4.69	105
Total Gross Profit	0.00	0.42	0.46	0.32	50	45	128	161	207	250
Total Revenue	0.17	0.42	0.46	0.32	50	46	134	176	235	283
Operating Revenue	0.01	-	0.46	0.32	50	46	134	176	235	283
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	1.09	5.66	14	28	33
Operating Cost of Revenue	0.00	-	-	0.00	0.00	1.09	5.66	14	28	33
Total Operating Expenses	25	47	57	91	154	225	240	253	212	145
Selling, General & Admin Expense	6.97	12	14	22	97	174	196	195	172	102
Research & Development Expense	15	34	41	53	50	51	45	50	21	33
Other Operating Expenses / (Income)	2.21	-0.20	-0.67	15	6.81	0.57	-1.52	8.38	-4.35	9.53
Restructuring Charge	-	-	-	-	-	-	0.00	0.00	23	1.65
Total Other Income / (Expense), net	1.73	-24	2.23	2.70	1.52	0.53	5.12	14	12	9.24
Interest Expense	-	-	-	-	-	0.00	0.00	2.78	4.84	4.33
Interest & Investment Income	-	-	2.23	2.70	1.52	0.53	5.12	17	17	14
Income Tax Expense	-	-	0.07	0.14	-0.09	0.76	1.83	0.55	1.70	-173
Basic Earnings per Share	($0.66)	($0.92)	($0.63)	($0.95)	($0.87)	($1.40)	($0.76)	($0.54)	$0.04	$2.14
Weighted Average Basic Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	141.92M	143.24M	143.06M	134.37M
Diluted Earnings per Share	($0.66)	($0.92)	($0.63)	($0.95)	($0.87)	($1.40)	($0.76)	($0.54)	$0.04	$2.07
Weighted Average Diluted Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	141.92M	143.24M	146.19M	138.70M
Weighted Average Basic & Diluted Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	142.58M	144.62M	137.34M	132.97M

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-13	-27	-11	0.72	14	0.96	23	22	32	211	34
Consolidated Net Income / (Loss)	-13	-27	-11	0.72	14	1.43	23	22	32	211	34
Net Income / (Loss) Continuing Operations	-13	-27	-11	0.72	14	1.43	23	22	32	211	34
Total Pre-Tax Income	-13	-26	-10	1.48	15	1.17	24	22	32	36	44
Total Operating Income	-16	-30	-13	-1.51	12	-1.67	22	20	30	33	41
Total Gross Profit	48	40	43	48	62	54	54	63	65	68	71
Total Revenue	55	45	50	57	68	60	62	70	73	77	78
Operating Revenue	55	45	50	57	68	60	62	70	73	77	78
Total Cost of Revenue	6.77	5.40	7.75	8.91	6.04	5.55	8.57	7.12	8.18	8.80	6.51
Operating Cost of Revenue	6.77	5.40	7.75	8.91	6.04	5.55	8.57	7.12	8.18	8.80	6.51
Total Operating Expenses	64	69	56	50	50	56	32	43	36	35	30
Selling, General & Admin Expense	48	50	48	45	42	37	20	26	26	29	22
Research & Development Expense	14	10	5.55	4.08	3.05	8.11	5.74	7.43	8.44	11	7.47
Other Operating Expenses / (Income)	2.65	9.07	-4.13	-0.29	4.57	-4.51	4.43	9.25	0.93	-5.07	0.28
Restructuring Charge	0.00	-	6.68	1.07	0.00	15	1.53	0.11	0.00	-	0.00
Total Other Income / (Expense), net	3.11	3.26	3.24	2.99	3.06	2.84	2.50	2.07	2.22	2.45	2.50
Interest Expense	1.40	1.31	1.28	1.20	1.21	1.15	1.07	1.12	1.10	1.05	1.01
Interest & Investment Income	4.51	4.57	4.53	4.19	4.27	3.99	3.57	3.19	3.32	3.50	3.52
Income Tax Expense	0.30	0.46	0.74	0.76	0.46	-0.26	1.01	0.64	0.41	-175	9.57
Basic Earnings per Share	($0.09)	($0.19)	($0.07)	$0.01	$0.10	-	$0.17	$0.16	$0.24	$1.57	$0.26
Weighted Average Basic Shares Outstanding	142.85M	143.24M	144.01M	143.33M	143.05M	143.06M	138.92M	134.87M	131.81M	134.37M	132.38M
Diluted Earnings per Share	($0.09)	($0.19)	($0.07)	$0.01	$0.10	-	$0.16	$0.16	$0.23	$1.52	$0.25
Weighted Average Diluted Shares Outstanding	142.85M	143.24M	144.01M	144.11M	145.65M	146.19M	143.20M	137.53M	136.01M	138.70M	137.64M
Weighted Average Basic & Diluted Shares Outstanding	143.61M	144.62M	143.02M	142.99M	143.18M	137.34M	135.10M	131.63M	131.84M	132.97M	128.60M

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	44	126	-48	188	-34	-40	-138	-45	35	-3.22
Net Cash From Operating Activities	-21	-41	-52	-64	-70	-158	-80	-33	44	136
Net Cash From Continuing Operating Activities	-21	-41	-52	-64	-70	-158	-80	-33	44	136
Net Income / (Loss) Continuing Operations	-23	-71	-53	-88	-103	-181	-108	-78	5.75	287
Consolidated Net Income / (Loss)	-23	-71	-53	-88	-103	-181	-108	-78	5.75	287
Depreciation Expense	-	0.02	0.02	0.03	1.37	2.76	2.71	12	19	19
Amortization Expense	1.29	-0.12	1.29	1.14	-	0.66	-1.57	-12	-13	-10
Non-Cash Adjustments To Reconcile Net Income	1.25	30	6.15	22	21	42	34	51	26	24
Changes in Operating Assets and Liabilities, net	-	-	-6.00	2.03	10	-22	-6.82	-5.61	5.45	-185
Net Cash From Investing Activities	31	-8.00	-0.07	7.78	-158	-104	-61	-6.71	39	-33
Net Cash From Continuing Investing Activities	31	-8.00	-0.07	7.78	-158	-104	-61	-6.71	39	-33
Purchase of Property, Plant & Equipment	-	-0.03	-0.07	-0.09	-7.34	-1.50	-0.29	-0.72	-0.28	-0.25
Purchase of Investments	-	-98	-36	0.00	-203	-445	-524	-524	-546	-527
Sale and/or Maturity of Investments	31	90	36	7.88	52	354	464	529	585	494
Other Investing Activities, net	-	-	-	0.00	0.00	-12	-0.66	-12	-0.04	0.00
Net Cash From Financing Activities	34	175	4.01	244	194	221	2.43	-5.13	-49	-106
Net Cash From Continuing Financing Activities	34	166	4.01	244	194	221	2.43	-5.13	-49	-106
Repurchase of Common Equity	-	-	-	-	-	-	0.00	0.00	-40	-98
Issuance of Common Equity	7.82	162	0.00	223	188	197	1.91	1.85	1.08	0.76
Other Financing Activities, net	-	4.14	4.01	21	6.64	24	0.52	-6.98	-9.94	-8.71
Cash Income Taxes Paid	-	-	0.00	0.06	0.26	0.26	1.98	0.50	2.18	2.82

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-35	2.48	16	-31	3.74	46	-17	-13	20	7.02	-39
Net Cash From Operating Activities	-13	14	-19	16	17	30	1.30	44	44	46	33
Net Cash From Continuing Operating Activities	-13	14	-19	16	17	30	1.30	44	44	46	33
Net Income / (Loss) Continuing Operations	-13	-27	-11	0.72	14	1.43	23	22	32	211	34
Consolidated Net Income / (Loss)	-13	-27	-11	0.72	14	1.43	23	22	32	211	34
Depreciation Expense	5.26	4.95	4.85	4.84	4.89	4.86	4.86	4.86	4.87	4.86	4.82
Amortization Expense	-3.24	-3.31	-3.21	-3.13	-3.42	-2.98	-2.66	-2.56	-2.63	-2.34	-2.32
Non-Cash Adjustments To Reconcile Net Income	12	20	1.27	7.62	13	4.32	0.73	15	6.69	2.04	-0.70
Changes in Operating Assets and Liabilities, net	-14	19	-11	5.78	-12	22	-25	5.73	3.97	-170	-3.59
Net Cash From Investing Activities	-20	-6.26	49	-39	-11	39	31	-13	-14	-37	-18
Net Cash From Continuing Investing Activities	-20	-6.26	49	-39	-11	39	31	-13	-14	-37	-18
Purchase of Property, Plant & Equipment	0.11	-0.30	-0.01	-	-	-0.28	-0.02	-0.10	-0.07	-0.07	-0.04
Purchase of Investments	-123	-144	-121	-197	-143	-85	-92	-145	-107	-182	-127
Sale and/or Maturity of Investments	103	138	171	158	133	124	123	132	94	145	109
Net Cash From Financing Activities	-2.33	-5.58	-15	-8.27	-2.72	-23	-49	-44	-10	-1.89	-54
Net Cash From Continuing Financing Activities	-2.33	-5.58	-15	-8.27	-2.72	-23	-49	-44	-10	-1.89	-54
Repurchase of Common Equity	-	-	-12	-6.13	-	-22	-47	-43	-8.67	-	-36
Other Financing Activities, net	-2.33	-7.43	-2.75	-2.14	-2.72	-2.33	-2.42	-2.23	-1.82	-2.24	-18
Cash Income Taxes Paid	0.06	0.16	0.00	1.46	-	0.73	0.25	0.82	2.03	-0.28	1.33

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	57	190	146	324	464	543	471	548	551	752
Total Current Assets	40	175	133	315	419	513	443	425	447	492
Cash & Equivalents	40	166	118	306	272	232	94	49	83	80
Short-Term Investments	0.00	7.83	7.89	0.00	126	234	295	302	275	318
Accounts Receivable	0.09	0.11	0.22	0.37	0.00	15	13	24	37	41
Inventories, net	-	-	-	0.00	14	19	25	40	39	46
Prepaid Expenses	-	1.68	6.78	8.75	7.17	12	14	9.49	11	5.75
Other Current Assets	-	-	-	-	-	0.80	1.33	1.03	1.13	1.08
Plant, Property, & Equipment, net	0.00	0.03	0.04	0.09	4.79	4.42	3.65	3.35	2.73	2.11
Total Noncurrent Assets	17	15	13	9.07	39	26	25	120	101	258
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	0.00	109	92	74
Intangible Assets	16	14	13	8.86	9.33	8.40	6.43	4.98	4.36	3.76
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	-	0.00	176
Other Noncurrent Operating Assets	1.71	0.45	0.36	0.21	5.74	17	18	6.02	4.89	3.69
Total Liabilities & Shareholders' Equity	57	190	146	324	464	543	471	548	551	752
Total Liabilities	21	24	33	26	56	64	65	170	173	170
Total Current Liabilities	5.79	8.15	7.26	11	32	41	46	77	98	94
Accounts Payable	5.79	7.96	7.07	11	25	35	40	4.33	5.19	3.31
Accrued Expenses	-	-	-	-	-	-	-	50	65	67
Current Deferred Revenue	-	0.12	0.12	-	-	0.19	3.15	4.81	11	3.72
Other Current Liabilities	-	-	-	0.12	7.20	5.51	2.97	18	17	20
Total Noncurrent Liabilities	50	12	22	14	24	24	19	93	75	77
Noncurrent Deferred Revenue	0.68	0.44	0.32	-	-	-	-	-	1.70	13
Other Noncurrent Operating Liabilities	50	-	-	14	24	24	19	93	74	64
Commitments & Contingencies	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.97	166	113	299	408	479	405	378	377	581
Total Preferred & Common Equity	0.97	166	113	299	408	479	405	378	377	581
Total Common Equity	0.97	166	113	299	408	479	405	378	377	581
Common Stock	-	499	505	772	984	1,236	1,271	1,321	1,315	1,231
Retained Earnings	-	-352	-416	-472	-575	-756	-864	-942	-937	-649
Accumulated Other Comprehensive Income / (Loss)	-	-0.88	-0.81	-0.81	-0.81	-0.85	-1.06	-0.73	-0.65	-0.60

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	488	452	549	555	517	524	549	505	503	528	724
Total Current Assets	460	424	416	426	398	410	440	406	409	439	480
Cash & Equivalents	86	89	82	46	64	33	37	66	53	73	41
Short-Term Investments	291	273	269	292	255	297	312	246	262	279	338
Accounts Receivable	42	19	19	38	29	26	36	40	40	31	49
Inventories, net	25	32	33	33	40	39	39	46	47	45	46
Prepaid Expenses	12	10	11	16	7.65	7.84	14	5.54	6.58	11	4.12
Other Current Assets	3.81	1.23	1.21	1.65	2.00	6.98	2.70	0.78	0.67	0.30	1.76
Plant, Property, & Equipment, net	3.76	3.84	3.65	3.50	3.20	3.04	2.89	2.58	2.42	2.27	1.99
Total Noncurrent Assets	25	24	129	125	115	111	106	97	91	87	242
Noncurrent Note & Lease Receivables	-	-	117	113	104	101	-	88	83	79	70
Intangible Assets	6.84	6.10	5.68	5.26	4.76	4.62	4.51	4.16	4.05	3.90	3.59
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	-	-	-	167
Other Noncurrent Operating Assets	18	18	6.23	6.13	5.90	5.16	102	4.78	3.93	3.81	1.75
Total Liabilities & Shareholders' Equity	488	452	549	555	517	524	549	505	503	528	724
Total Liabilities	65	61	157	163	157	159	161	155	167	162	156
Total Current Liabilities	42	42	62	74	71	77	79	68	78	76	87
Accounts Payable	40	36	41	52	50	56	57	4.22	3.31	2.21	2.66
Accrued Expenses	-	-	-	-	-	-	-	42	50	50	58
Current Deferred Revenue	-	3.16	3.23	4.66	4.91	4.37	4.30	4.59	5.50	4.60	5.04
Other Current Liabilities	1.64	2.92	17	17	16	16	18	17	20	20	21
Total Noncurrent Liabilities	23	19	95	89	86	82	83	86	89	86	70
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	12	12	12	12
Other Noncurrent Operating Liabilities	23	19	95	89	86	82	83	74	77	73	57
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	423	390	392	392	359	365	388	350	335	366	568
Total Preferred & Common Equity	423	390	392	392	359	365	388	350	335	366	568
Total Common Equity	423	390	392	392	359	365	388	350	335	366	568
Common Stock	1,263	1,282	1,295	1,308	1,313	1,318	1,326	1,264	1,228	1,227	1,184
Retained Earnings	-838	-891	-902	-915	-953	-952	-938	-913	-892	-860	-615
Accumulated Other Comprehensive Income / (Loss)	-1.53	-0.99	-1.02	-0.95	-0.85	-0.86	-0.39	-0.83	-0.91	-0.75	-0.88

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	141.62%	10.77%	-31.32%	15,660.38%	-9.00%	193.89%	30.95%	33.97%	20.38%
EBITDA Growth	0.00%	-222.13%	23.93%	-66.47%	-14.64%	-72.29%	37.77%	16.45%	102.20%	5,533.15%
EBIT Growth	0.00%	-203.89%	21.97%	-64.63%	-14.68%	-73.30%	38.32%	17.74%	94.89%	2,338.40%
NOPAT Growth	0.00%	-87.27%	-17.86%	-64.63%	-14.68%	-73.30%	38.32%	17.74%	94.36%	7,391.96%
Net Income Growth	0.00%	-203.89%	25.02%	-66.52%	-16.17%	-76.24%	40.22%	27.88%	107.37%	4,893.08%
EPS Growth	0.00%	-39.39%	31.52%	-50.79%	8.42%	-60.92%	45.71%	28.95%	107.41%	5,075.00%
Operating Cash Flow Growth	0.00%	-98.33%	-25.36%	-23.20%	-9.87%	-125.73%	49.57%	57.93%	232.66%	205.62%
Free Cash Flow Firm Growth	0.00%	0.00%	45.44%	-1.04%	-49.64%	-135.99%	47.53%	6.98%	106.16%	2,045.84%
Invested Capital Growth	0.00%	120.34%	58.84%	-159.38%	-101.63%	186.99%	23.30%	69.92%	-30.30%	864.81%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-36.86%	3.90%	10.49%	6.70%	6.49%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-16.09%	2.23%	1.51%	107.73%	45.22%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-15.79%	3.97%	-1.75%	85.66%	49.86%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-15.79%	3.97%	-1.75%	84.18%	285.77%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-16.21%	6.30%	-1.07%	125.51%	268.98%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-14.75%	7.32%	-1.89%	126.67%	276.36%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-22.65%	31.38%	10.35%	55.28%	12.95%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	30.28%	-8.20%	153.03%	6.30%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	10.54%	-65.70%	-48.93%	-51.59%	1,213.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.58%	100.00%	100.00%	100.00%	100.00%	97.61%	95.77%	91.94%	87.99%	88.46%
EBITDA Margin	-12,720.23%	-16,958.85%	-11,647.30%	-28,230.19%	-205.35%	-388.80%	-82.32%	-52.52%	0.86%	40.34%
Operating Margin	-14,466.47%	-11,212.44%	-11,930.89%	-28,598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%	37.06%
EBIT Margin	-13,465.32%	-16,935.89%	-11,930.89%	-28,598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%	37.06%
Profit (Net Income) Margin	-13,465.32%	-16,935.89%	-11,464.15%	-27,794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%	101.47%
Tax Burden Percent	100.00%	100.00%	100.14%	100.16%	99.91%	100.42%	101.72%	100.71%	77.23%	251.59%
Interest Burden Percent	100.00%	100.00%	95.96%	97.03%	98.55%	99.71%	95.41%	84.49%	-158.91%	108.81%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.77%	-151.59%
Return on Invested Capital (ROIC)	0.00%	0.00%	-379.84%	-2,508.77%	0.00%	0.00%	-537.06%	-296.40%	-15.65%	260.90%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-368.67%	-2,496.60%	0.00%	0.00%	-530.01%	-292.66%	-18.29%	254.75%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	341.70%	2,465.78%	0.00%	0.00%	512.60%	276.48%	17.17%	-200.99%
Return on Equity (ROE)	-2,399.07%	-84.93%	-38.14%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%	59.91%
Cash Return on Invested Capital (CROIC)	0.00%	-1,008.79%	-425.30%	0.00%	0.00%	-1,187.17%	-557.93%	-348.21%	20.07%	98.47%
Operating Return on Assets (OROA)	-40.87%	-57.36%	-32.91%	-38.69%	-26.47%	-35.89%	-21.98%	-18.00%	-0.85%	16.11%
Return on Assets (ROA)	-40.87%	-57.36%	-31.62%	-37.60%	-26.06%	-35.94%	-21.33%	-15.31%	1.05%	44.11%
Return on Common Equity (ROCE)	-2,399.07%	-84.93%	-38.14%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%	59.91%
Return on Equity Simple (ROE_SIMPLE)	-2,399.07%	-42.71%	-47.15%	-29.60%	-25.18%	-37.77%	-26.68%	-20.64%	1.52%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	-33	-39	-64	-73	-127	-78	-64	-3.62	264
NOPAT Margin	-10,126.53%	-7,848.71%	-8,351.62%	-20,018.90%	-145.66%	-277.41%	-58.22%	-36.57%	-1.54%	93.25%
Net Nonoperating Expense Percent (NNEP)	-14.57%	-38.46%	-11.17%	-12.18%	-8.14%	-12.25%	-7.05%	-3.74%	2.64%	6.15%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-19.25%	-16.98%	-0.96%	45.40%
Cost of Revenue to Revenue	2.31%	0.00%	0.00%	0.00%	0.00%	2.39%	4.23%	8.06%	12.01%	11.54%
SG&A Expenses to Revenue	4,028.90%	2,893.78%	2,957.67%	7,024.53%	194.09%	380.52%	146.51%	111.12%	73.16%	35.96%
R&D to Revenue	8,401.16%	8,117.22%	8,937.80%	16,624.53%	100.42%	112.13%	33.57%	28.28%	8.84%	11.48%
Operating Expenses to Revenue	14,564.16%	11,312.44%	12,318.57%	28,698.43%	308.09%	493.91%	178.94%	144.18%	89.98%	51.40%
Earnings before Interest and Taxes (EBIT)	-23	-71	-55	-91	-104	-181	-111	-92	-4.69	105
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-71	-54	-90	-103	-177	-110	-92	2.03	114
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.09	5.80	3.79	6.19	1.51	3.42	3.41	3.62
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.73	5.98	3.88	6.30	1.54	3.46	3.45	3.64
Price to Revenue (P/Rev)	0.00	0.00	1,238.08	5,447.28	30.85	65.03	4.58	7.36	5.47	7.43
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	223.53	7.32
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.45%	13.66%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	37.55	0.00	0.00	192.08	13.99	34.49	48.80	9.30
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	1,013.23	4,484.95	22.42	54.81	1.68	5.36	3.94	6.02
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	457.46	14.93
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	16.25
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.46
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.89	12.57
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.75	17.11
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.07	0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.07	0.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-40.83	-1.18	-0.93	-0.99	-1.03	-1.00	-0.97	-0.94	-0.94	-0.79
Leverage Ratio	58.70	1.48	1.21	1.14	1.12	1.14	1.15	1.30	1.45	1.36
Compound Leverage Factor	58.70	1.48	1.16	1.11	1.10	1.13	1.09	1.10	-2.31	1.48
Debt to Total Capital	0.00%	6.64%	16.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	6.64%	16.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	93.36%	83.81%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.17	-0.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	2.28	1.93	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.17	-0.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.36	-0.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	4.93	2.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.36	-0.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	6.13	38.60	15.22	25.76	3.57	2.68	3.23	7.67
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.86	21.50	18.30	27.90	13.11	12.63	9.60	5.50	4.57	5.25
Quick Ratio	6.86	21.30	17.36	27.13	12.45	11.85	8.74	4.85	4.04	4.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-79	-43	-44	-65	-154	-81	-75	4.64	100
Operating Cash Flow to CapEx	0.00%	-164,676.00%	-69,744.59%	-74,805.88%	-951.36%	-10,505.80%	-27,235.96%	-4,660.31%	15,796.44%	53,832.54%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-27.17	0.96	23.01
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-12.06	9.18	31.33
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-12.32	9.12	31.27
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.13	0.09	0.26	0.34	0.43	0.43
Accounts Receivable Turnover	2.01	4.29	2.84	1.09	0.00	0.00	9.28	9.34	7.76	7.26
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.07	0.26	0.44	0.72	0.77
Fixed Asset Turnover	0.00	0.00	12.86	4.75	20.54	9.91	33.23	50.12	77.28	116.92
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.04	0.15	0.64	5.94	7.69
Days Sales Outstanding (DSO)	181.45	85.14	128.50	335.73	0.00	0.00	39.35	39.07	47.06	50.29
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	5,562.49	1,420.24	831.45	509.96	474.44
Days Payable Outstanding (DPO)	528,428.75	0.00	0.00	0.00	0.00	9,993.84	2,414.55	571.66	61.47	47.49
Cash Conversion Cycle (CCC)	-528,247.30	85.14	128.50	335.73	0.00	-4,431.35	-954.96	298.86	495.55	477.24
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-39	7.87	12	-7.42	-15	13	16	27	19	183
Invested Capital Turnover	0.00	-0.03	0.05	0.13	-4.48	-46.87	9.23	8.11	10.16	2.80
Increase / (Decrease) in Invested Capital	0.00	47	4.63	-20	-7.54	28	3.03	11	-8.26	164
Enterprise Value (EV)	0.00	0.00	469	1,426	1,123	2,499	225	940	927	1,705
Market Capitalization	0.00	0.00	573	1,732	1,546	2,966	614	1,291	1,286	2,103
Book Value per Share	$0.00	$1.97	$1.34	$3.49	$3.65	$3.69	$2.85	$2.63	$2.64	$4.41
Tangible Book Value per Share	$0.00	$1.80	$1.19	$3.39	$3.56	$3.63	$2.81	$2.60	$2.61	$4.38
Total Capital	0.97	178	134	299	408	479	405	378	377	581
Total Debt	0.00	12	22	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	12	22	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-40	-162	-104	-306	-423	-466	-389	-351	-358	-398
Capital Expenditures (CapEx)	-0.02	0.03	0.07	0.09	7.34	1.50	0.29	0.72	0.28	0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.71	-6.36	-0.27	-2.18	-11	6.60	7.04	-2.88	-9.64	0.25
Debt-free Net Working Capital (DFNWC)	34	167	126	304	387	473	396	348	349	398
Net Working Capital (NWC)	34	167	126	304	387	473	396	348	349	398
Net Nonoperating Expense (NNE)	5.78	38	14	25	30	54	30	14	-9.37	-23
Net Nonoperating Obligations (NNO)	-40	-158	-100	-306	-423	-466	-389	-351	-358	-398
Total Depreciation and Amortization (D&A)	1.29	-0.10	1.31	1.17	1.37	3.42	1.13	-0.49	6.71	9.27
Debt-free, Cash-free Net Working Capital to Revenue	-3,297.69%	-1,521.53%	-58.10%	-684.59%	-21.75%	14.47%	5.25%	-1.64%	-4.10%	0.09%
Debt-free Net Working Capital to Revenue	19,620.81%	39,976.56%	27,124.62%	95,547.80%	773.04%	1,036.46%	295.78%	198.05%	148.36%	140.69%
Net Working Capital to Revenue	19,620.81%	39,976.56%	27,124.62%	95,547.80%	773.04%	1,036.46%	295.78%	198.05%	148.36%	140.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	($1.40)	($0.76)	($0.54)	$0.04	$2.14
Adjusted Weighted Average Basic Shares Outstanding	0.00	84.05M	85.50M	111.80M	127.45M	141.65M	141.92M	143.24M	143.06M	134.37M
Adjusted Diluted Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	($1.40)	($0.76)	($0.54)	$0.04	$2.07
Adjusted Weighted Average Diluted Shares Outstanding	0.00	84.05M	85.50M	111.80M	127.45M	141.65M	141.92M	143.24M	146.19M	138.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	84.05M	85.50M	111.80M	118.47M	129.37M	142.58M	144.62M	137.34M	132.97M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-33	-39	-64	-73	-127	-78	-64	14	75
Normalized NOPAT Margin	-10,126.53%	-7,848.71%	-8,351.62%	-20,018.90%	-145.66%	-277.41%	-58.22%	-36.57%	6.05%	26.35%
Pre Tax Income Margin	-13,465.32%	-16,935.89%	-11,448.38%	-27,748.74%	-205.06%	-395.15%	-79.35%	-44.14%	3.17%	40.33%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.04	-0.97	24.23
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-23.13	-0.75	60.96
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.30	-1.03	24.17
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-23.39	-0.81	60.90
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	699.57%	34.18%

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	132,970,979.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	132,970,979.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.26
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-2.27%	58.59%	46.19%	37.83%	24.32%	32.76%	24.18%	22.41%	8.41%	28.81%	24.40%
EBITDA Growth	-57.24%	4.79%	63.11%	101.11%	192.85%	100.76%	307.09%	10,819.02%	141.94%	16,614.02%	82.64%
EBIT Growth	-71.21%	-5.60%	55.20%	90.64%	172.24%	94.38%	264.85%	1,427.36%	153.19%	2,091.55%	89.60%
NOPAT Growth	-71.21%	-5.60%	55.20%	93.47%	200.01%	90.21%	325.77%	2,738.38%	157.90%	9,755.37%	54.68%
Net Income Growth	-49.59%	-3.18%	58.98%	106.28%	206.72%	105.32%	317.17%	2,879.64%	119.87%	14,651.15%	47.17%
EPS Growth	-50.00%	-5.56%	61.11%	112.50%	211.11%	0.00%	328.57%	1,500.00%	130.00%	0.00%	56.25%
Operating Cash Flow Growth	13.57%	36.96%	41.28%	660.62%	228.26%	110.41%	106.99%	179.25%	161.02%	51.65%	2,404.62%
Free Cash Flow Firm Growth	56.82%	-40.92%	2.20%	133.06%	241.84%	119.47%	216.46%	382.38%	114.19%	413.52%	-617.59%
Invested Capital Growth	14.12%	69.92%	36.33%	-18.37%	-26.47%	-30.30%	-5.27%	-40.58%	-64.43%	864.81%	406.43%
Revenue Q/Q Growth	31.38%	-17.28%	11.55%	13.70%	18.50%	-11.66%	4.34%	12.08%	4.94%	4.96%	0.77%
EBITDA Q/Q Growth	22.78%	-96.87%	58.57%	101.77%	6,348.78%	-98.38%	11,136.92%	-6.92%	42.89%	11.83%	22.79%
EBIT Q/Q Growth	-0.58%	-82.46%	55.34%	88.58%	876.47%	-114.21%	1,408.99%	-8.07%	48.11%	11.75%	24.62%
NOPAT Q/Q Growth	-0.58%	-82.46%	55.34%	92.03%	1,640.45%	-117.86%	1,130.14%	-6.90%	50.58%	568.60%	-83.50%
Net Income Q/Q Growth	-17.01%	-99.86%	60.00%	106.72%	1,887.53%	-90.04%	1,533.59%	-7.84%	46.66%	568.11%	-83.70%
EPS Q/Q Growth	-12.50%	-111.11%	63.16%	114.29%	900.00%	0.00%	0.00%	0.00%	43.75%	560.87%	-83.55%
Operating Cash Flow Q/Q Growth	-369.82%	207.80%	-229.95%	185.19%	7.49%	76.84%	-95.68%	3,303.15%	0.47%	2.74%	-28.70%
Free Cash Flow Firm Q/Q Growth	13.79%	-77.83%	38.21%	134.89%	269.92%	-75.59%	269.60%	44.54%	64.26%	-41.48%	-472.53%
Invested Capital Q/Q Growth	28.40%	-48.93%	44.38%	-13.78%	15.65%	-51.59%	96.24%	-45.91%	-30.77%	1,213.00%	3.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.58%	88.04%	84.59%	84.42%	91.10%	90.73%	86.27%	89.84%	88.87%	88.59%	91.63%
EBITDA Margin	-26.12%	-62.16%	-23.08%	0.36%	19.51%	0.36%	38.50%	31.97%	43.54%	46.38%	56.52%
Operating Margin	-29.83%	-65.80%	-26.35%	-2.65%	17.33%	-2.79%	34.97%	28.69%	40.49%	43.10%	53.31%
EBIT Margin	-29.83%	-65.80%	-26.35%	-2.65%	17.33%	-2.79%	34.97%	28.69%	40.49%	43.10%	53.31%
Profit (Net Income) Margin	-24.67%	-59.60%	-21.37%	1.26%	21.17%	2.39%	37.37%	30.73%	42.95%	273.35%	44.21%
Tax Burden Percent	102.27%	101.74%	107.38%	48.85%	96.91%	121.82%	95.87%	97.10%	98.71%	590.62%	78.21%
Interest Burden Percent	80.85%	89.02%	75.53%	-97.69%	126.04%	-70.28%	111.45%	110.32%	107.45%	107.37%	106.04%
Effective Tax Rate	0.00%	0.00%	0.00%	51.15%	3.09%	-21.82%	4.13%	2.90%	1.29%	-490.62%	21.79%
Return on Invested Capital (ROIC)	-66.23%	-373.34%	-103.46%	-7.09%	79.92%	-34.52%	216.35%	267.79%	399.24%	712.29%	110.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-65.66%	-371.69%	-103.03%	-7.52%	79.06%	-35.50%	215.59%	267.17%	398.62%	708.46%	109.43%
Return on Net Nonoperating Assets (RNNOA)	57.59%	351.14%	93.65%	6.77%	-69.67%	33.32%	-192.31%	-246.52%	-370.47%	-558.95%	-82.47%
Return on Equity (ROE)	-8.64%	-22.20%	-9.81%	-0.32%	10.25%	-1.20%	24.05%	21.28%	28.77%	153.33%	27.53%
Cash Return on Invested Capital (CROIC)	-139.14%	-348.21%	-185.36%	-92.31%	-18.90%	20.07%	81.04%	237.46%	352.19%	98.47%	111.48%
Operating Return on Assets (OROA)	-9.08%	-22.67%	-10.41%	-1.02%	6.92%	-1.19%	16.93%	14.54%	19.99%	18.74%	25.88%
Return on Assets (ROA)	-7.51%	-20.53%	-8.45%	0.49%	8.45%	1.02%	18.09%	15.58%	21.20%	118.83%	21.46%
Return on Common Equity (ROCE)	-8.64%	-22.20%	-9.81%	-0.32%	10.25%	-1.20%	24.05%	21.28%	28.77%	153.33%	27.53%
Return on Equity Simple (ROE_SIMPLE)	-19.70%	0.00%	-17.40%	-13.81%	-5.81%	0.00%	11.38%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-11	-21	-9.28	-0.74	11	-2.03	21	20	29	196	32
NOPAT Margin	-20.88%	-46.06%	-18.44%	-1.29%	16.80%	-3.40%	33.53%	27.85%	39.97%	254.58%	41.69%
Net Nonoperating Expense Percent (NNEP)	-0.58%	-1.65%	-0.43%	0.43%	0.86%	0.98%	0.76%	0.62%	0.62%	3.83%	0.57%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.50%	-	-	-	-0.54%	5.98%	5.82%	8.03%	33.77%	5.71%
Cost of Revenue to Revenue	12.42%	11.96%	15.41%	15.58%	8.91%	9.27%	13.73%	10.16%	11.13%	11.41%	8.37%
SG&A Expenses to Revenue	87.61%	111.04%	94.82%	78.57%	62.51%	61.86%	32.56%	37.16%	35.64%	37.94%	28.35%
R&D to Revenue	24.96%	22.68%	11.04%	7.13%	4.50%	13.54%	9.19%	10.62%	11.48%	14.13%	9.61%
Operating Expenses to Revenue	117.42%	153.84%	110.94%	87.07%	73.76%	93.51%	51.30%	61.15%	48.38%	45.49%	38.32%
Earnings before Interest and Taxes (EBIT)	-16	-30	-13	-1.51	12	-1.67	22	20	30	33	41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-28	-12	0.21	13	0.21	24	22	32	36	44
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.84	3.42	2.00	2.24	2.70	3.41	3.15	3.41	3.98	3.62	3.47
Price to Tangible Book Value (P/TBV)	2.88	3.46	2.03	2.27	2.73	3.45	3.19	3.45	4.02	3.64	3.49
Price to Revenue (P/Rev)	7.02	7.36	3.76	3.94	4.76	5.47	4.47	4.40	5.47	7.43	6.61
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	223.53	27.71	18.87	18.69	7.32	6.61
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.45%	3.61%	5.30%	5.35%	13.66%	15.13%
Enterprise Value to Invested Capital (EV/IC)	14.53	34.49	10.15	14.32	17.82	48.80	21.22	41.11	78.97	9.30	8.43
Enterprise Value to Revenue (EV/Rev)	4.88	5.36	2.09	2.35	3.17	3.94	3.20	3.19	4.15	6.02	5.34
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	457.46	21.00	13.85	14.02	14.93	11.87
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	26.02	15.94	15.75	16.25	12.79
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	27.30	16.43	16.12	6.46	5.73
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	24.47	20.89	12.31	8.95	9.18	12.57	9.54
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	199.75	25.48	12.91	11.77	17.11	12.63
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.88	-0.94	-0.91	-0.90	-0.88	-0.94	-0.89	-0.92	-0.93	-0.79	-0.75
Leverage Ratio	1.28	1.30	1.29	1.42	1.42	1.45	1.44	1.47	1.43	1.36	1.34
Compound Leverage Factor	1.03	1.16	0.98	-1.38	1.78	-1.02	1.60	1.62	1.54	1.46	1.42
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.74	3.05	1.21	1.69	2.77	3.25	3.19	3.06	4.63	7.36	7.63
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.77	5.50	5.60	5.33	5.60	4.57	5.93	5.23	5.76	5.25	5.55
Quick Ratio	5.09	4.85	4.91	4.63	4.90	4.04	5.16	4.54	5.02	4.69	4.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-18	-32	-20	6.90	26	6.23	23	33	55	32	-119
Operating Cash Flow to CapEx	0.00%	4,786.62%	0.00%	0.00%	0.00%	10,716.73%	7,647.06%	45,143.88%	68,383.08%	63,427.78%	83,487.18%
Free Cash Flow to Firm to Interest Expense	-12.85	-24.42	-15.41	5.76	21.12	5.44	21.58	29.79	49.73	30.55	-117.74
Operating Cash Flow to Interest Expense	-9.48	10.93	-14.50	13.22	14.10	26.28	1.22	39.61	40.44	43.62	32.17
Operating Cash Flow Less CapEx to Interest Expense	-9.41	10.70	-14.50	13.22	14.10	26.03	1.20	39.52	40.39	43.55	32.14
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.34	0.40	0.39	0.40	0.43	0.48	0.51	0.49	0.43	0.49
Accounts Receivable Turnover	3.99	9.34	7.98	9.20	5.92	7.76	7.14	7.93	7.91	7.26	6.66
Inventory Turnover	0.35	0.44	0.60	0.80	0.79	0.72	0.68	0.64	0.70	0.77	0.66
Fixed Asset Turnover	43.80	50.12	54.38	61.89	69.05	77.28	85.66	95.21	103.17	116.92	130.77
Accounts Payable Turnover	0.22	0.64	0.50	0.59	0.52	5.94	1.07	0.91	1.00	7.69	8.89
Days Sales Outstanding (DSO)	91.58	39.07	45.72	39.67	61.64	47.06	51.11	46.04	46.15	50.29	54.77
Days Inventory Outstanding (DIO)	1,048.99	831.45	607.56	455.90	464.74	509.96	539.63	571.11	518.05	474.44	552.37
Days Payable Outstanding (DPO)	1,667.71	571.66	732.71	619.42	708.66	61.47	342.09	399.93	365.92	47.49	41.04
Cash Conversion Cycle (CCC)	-527.13	298.86	-79.42	-123.85	-182.28	495.55	248.65	217.21	198.28	477.24	566.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	53	27	39	34	39	19	37	20	14	183	189
Invested Capital Turnover	3.17	8.11	5.61	5.48	4.76	10.16	6.45	9.61	9.99	2.80	2.64
Increase / (Decrease) in Invested Capital	6.61	11	10	-7.64	-14	-8.26	-2.08	-14	-25	164	152
Enterprise Value (EV)	776	940	399	486	699	927	791	829	1,103	1,705	1,592
Market Capitalization	1,114	1,291	719	817	1,048	1,286	1,104	1,144	1,455	2,103	1,971
Book Value per Share	$2.73	$2.63	$2.50	$2.55	$2.71	$2.64	$2.55	$2.48	$2.78	$4.41	$4.27
Tangible Book Value per Share	$2.70	$2.60	$2.46	$2.52	$2.68	$2.61	$2.52	$2.45	$2.75	$4.38	$4.24
Total Capital	392	378	359	365	388	377	350	335	366	581	568
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-338	-351	-320	-331	-349	-358	-313	-315	-352	-398	-379
Capital Expenditures (CapEx)	-0.11	0.30	0.00	0.00	0.00	0.28	0.02	0.10	0.07	0.07	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	15	-2.88	7.26	2.29	13	-9.64	24	16	11	0.25	15
Debt-free Net Working Capital (DFNWC)	353	348	327	333	362	349	337	331	363	398	394
Net Working Capital (NWC)	353	348	327	333	362	349	337	331	363	398	394
Net Nonoperating Expense (NNE)	2.06	6.10	1.47	-1.46	-2.96	-3.46	-2.40	-2.01	-2.19	-14	-1.96
Net Nonoperating Obligations (NNO)	-338	-351	-320	-331	-349	-358	-313	-315	-352	-398	-379
Total Depreciation and Amortization (D&A)	2.03	1.64	1.64	1.72	1.47	1.88	2.20	2.30	2.24	2.53	2.50
Debt-free, Cash-free Net Working Capital to Revenue	9.24%	-1.64%	3.79%	1.10%	5.95%	-4.10%	9.89%	5.99%	4.03%	0.09%	5.00%
Debt-free Net Working Capital to Revenue	221.95%	198.05%	170.93%	160.67%	164.21%	148.36%	136.42%	127.14%	136.38%	140.69%	131.98%
Net Working Capital to Revenue	221.95%	198.05%	170.93%	160.67%	164.21%	148.36%	136.42%	127.14%	136.38%	140.69%	131.98%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.09)	($0.19)	($0.07)	$0.01	$0.10	$0.00	$0.17	$0.16	$0.24	$1.57	$0.26
Adjusted Weighted Average Basic Shares Outstanding	142.85M	143.24M	144.01M	143.33M	143.05M	143.06M	138.92M	134.87M	131.81M	134.37M	132.38M
Adjusted Diluted Earnings per Share	($0.09)	($0.19)	($0.07)	$0.01	$0.10	$0.00	$0.16	$0.16	$0.23	$1.52	$0.25
Adjusted Weighted Average Diluted Shares Outstanding	142.85M	143.24M	144.01M	144.11M	145.65M	146.19M	143.20M	137.53M	136.01M	138.70M	137.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	143.61M	144.62M	143.02M	142.99M	143.18M	137.34M	135.10M	131.63M	131.84M	132.97M	128.60M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-21	-4.60	-0.31	11	9.58	22	20	29	23	32
Normalized NOPAT Margin	-20.88%	-46.06%	-9.14%	-0.54%	16.80%	16.00%	35.88%	28.01%	39.97%	30.17%	41.69%
Pre Tax Income Margin	-24.12%	-58.58%	-19.90%	2.58%	21.85%	1.96%	38.98%	31.65%	43.50%	46.28%	56.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-11.62	-22.65	-10.33	-1.26	9.73	-1.46	20.48	17.98	27.07	31.75	40.93
NOPAT to Interest Expense	-8.13	-15.86	-7.23	-0.62	9.43	-1.77	19.63	17.46	26.72	187.51	32.01
EBIT Less CapEx to Interest Expense	-11.54	-22.88	-10.33	-1.26	9.73	-1.70	20.46	17.89	27.01	31.68	40.89
NOPAT Less CapEx to Interest Expense	-8.06	-16.08	-7.23	-0.62	9.43	-2.02	19.61	17.37	26.66	187.44	31.97
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	699.57%	187.88%	183.54%	154.12%	34.18%	29.31%

Financials Breakdown Chart

Key Financial Trends

Aurinia Pharmaceuticals (AUPH) has shown a pattern of growing revenue and solid profitability across the latest four quarterly reports, with healthy cash flow and a manageable balance sheet. It’s important to note that Q4 2025 included a sizable one-time tax benefit that boosted net income for that quarter. Below are the key takeaways for retail investors.

Rising quarterly revenue: Operating revenue increased each quarter in the period, rising from about $62.5M in Q1 2025 to $77.1M in Q4 2025.
Stable, strong gross margins: Gross margin ran in the mid-to-upper 80s percent range across the four quarters (roughly 86%–89%).
Consistent operating profitability: Total operating income was positive in all four quarters, with Q4 2025 at about $33.2M.
Net income positive across the period: Net income (continuing operations) was positive each quarter; Q4 2025 benefited from a large one-time tax credit, lifting reported net income for that quarter to about $210.8M.
Healthy liquidity position: Cash plus short-term investments on the balance sheet were substantial (roughly $351M in mid-2025), and cash balances ranged in the $66–$73M band across the latest quarters, supporting ongoing operations and investments.
Free cash flow stability over three quarters: Three of the four latest quarters generated roughly $31M of free cash flow (free cash flow = operating cash flow minus capital expenditures), with Q4 2025 being somewhat lower due to higher investing outflows.
Moderate leverage: Total liabilities and equity show a modest leverage profile (liabilities around $150–162M vs. equity around $335–366M in the period), indicating manageable debt levels for the business.
EPS influenced by one-time items: EPS metrics varied quarter to quarter, with Q4 2025 showing a large spike due to the tax benefit; excluding that item, quarterly EPS remained in the low-to-mid range historically.
Significant investing outflows: Cash used for purchasing investments was substantial in Q2–Q4 2025 (e.g., about $145M in Q2, $107M in Q3, and $182M in Q4), which reduced near-term cash despite overall strong operating cash flow.
Financing activity muted or negative: Net cash from financing activities was negative in several quarters, implying limited external financing activity and reliance on operating cash flow and investment activity for liquidity.

05/27/26 05:18 AM ETAI Generated. May Contain Errors.

Aurinia Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aurinia Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Aurinia Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $287.20 million in 2025, falling from -$23.30 million in 2016. The previous period was $5.75 million in 2024. View Aurinia Pharmaceuticals' forecast to see where analysts expect Aurinia Pharmaceuticals to go next.

Aurinia Pharmaceuticals' total operating income in 2025 was $104.91 million, based on the following breakdown:

Total Gross Profit: $250.39 million
Total Operating Expenses: $145.48 million

Over the last 9 years, Aurinia Pharmaceuticals' total revenue changed from $173 thousand in 2016 to $283.06 million in 2025, a change of 163,515.6%.

Aurinia Pharmaceuticals' total liabilities were at $170.26 million at the end of 2025, a 1.7% decrease from 2024, and a 708.9% increase since 2016.

In the past 9 years, Aurinia Pharmaceuticals' cash and equivalents has ranged from $39.65 million in 2016 to $306.02 million in 2019, and is currently $80.21 million as of their latest financial filing in 2025.

Over the last 9 years, Aurinia Pharmaceuticals' book value per share changed from 0.00 in 2016 to 4.41 in 2025, a change of 440.9%.

Related Companies

Financial statements for NASDAQ:AUPH last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Financials

Financials Breakdown Chart

Key Financial Trends

Aurinia Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Financials

Annual Income Statements for Aurinia Pharmaceuticals

Quarterly Income Statements for Aurinia Pharmaceuticals

Annual Cash Flow Statements for Aurinia Pharmaceuticals

Quarterly Cash Flow Statements for Aurinia Pharmaceuticals

Annual Balance Sheets for Aurinia Pharmaceuticals

Quarterly Balance Sheets for Aurinia Pharmaceuticals

Annual Metrics And Ratios for Aurinia Pharmaceuticals

Quarterly Metrics And Ratios for Aurinia Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Aurinia Pharmaceuticals Financials - Frequently Asked Questions

When does Aurinia Pharmaceuticals' fiscal year end?

How has Aurinia Pharmaceuticals' net income changed over the last 9 years?

What is Aurinia Pharmaceuticals' operating income?

How has Aurinia Pharmaceuticals' revenue changed over the last 9 years?

How much debt does Aurinia Pharmaceuticals have?

How much cash does Aurinia Pharmaceuticals have?

How has Aurinia Pharmaceuticals' book value per share changed over the last 9 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools